After the dose escalation stage, adult patients will be enrolled on the 5-aza stage where they will receive the drug 5-aza followed by two infusions of T cells on dose level 2. Patients will be given 3 cycles of 5-aza (administered daily through a vein for 5 days, every 28 days) followed by 2 doses of multiTAA-specific T cells administered 14 days apart. Before the patient is given the 5-aza they will be given a drug to help prevent nausea and vomiting.